Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

INSULIN LISPRO

All injection strengths: Limited Use (codes 646)

Other products in the same Health Canada class (A10A, A10AB) — coverage varies; not interchangeable

  • Insulin zinc crystalline human biosynthetic rdna origin (Humulin Regular): general benefit
  • Insulin aspart (NovoRapid): general benefit, Limited Use 646
  • Insulin glulisine dna origin (Apidra): general benefit
  • Insulin human biosynthetic (Novolin ge Toronto): general benefit
  • Human biosynthetic + insulin (Entuzity KwikPen): general benefit

Humalog · DIN 02229704 · 100U/mL · injection solution-10mL Pk

Limited Use — Reason for Use code 646 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 646 required
Write on scriptLU code 646 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 646
Reason for Use code 646 Patient uses an insulin pump that has not been declared compatible with a funded biosimilar version by the insulin pump manufacturer's product labeling. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Humalog · DIN 02229704 Manufacturer: Eli Lilly Canada Inc.; listing date 1998-12-31 Health Canada: Marketed since 1997-09-17 · brand HUMALOG · ATC A10AB04 INSULIN LISPRO · form Solution · route Intravenous, Subcutaneous, Intramuscular · ingredients INSULIN LISPRO 100 UNIT/ML · company Eli lilly canada inc · schedule Schedule d
Check this DIN again · Health Canada product record

Humalog: Formulary list price $37.1500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $37.1500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47871 · Verify on the e-Formulary ↗ (DIN 02229704)

Source record
DIN 02229704: Humalog Raw flags: insOH=Y, sec12=Y, sec3=Y Item: 682010015; group id 774; item number 1886; lccId 00368; manufacturer id LIL Source form: Inj Sol-10mL Pk; strength: 100U/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag Source prices (unrounded): $37.1500; ministry $37.1500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02229704 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47871
Shortage status: discontinued (2024-12-10, reported by ELI LILLY CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02229704
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:20:10 Insulins (Rapid Acting)) and how they are covered

Matched class: 68:20:10 Insulins (Rapid Acting)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: INSULIN (ZINC CRYSTALLINE) HUMAN BIOSYNTHETIC (RDNA ORIGIN), INSULIN GLULISINE (DNA ORIGIN), INSULIN HUMAN BIOSYNTHETIC, INSULIN INJECTION, HUMAN BIOSYNTHETIC Some products covered without a code (check the product listing): INSULIN ASPART 68:20:10 Insulins (Rapid Acting)

INSULIN (ZINC CRYSTALLINE) HUMAN BIOSYNTHETIC (RDNA ORIGIN)

· 2 products · General benefit · strengths: 1000U/10mL, 100U/mL · Inj Sol-10mL Pk, Inj Sol-5x3mL Pk

INSULIN ASPART

· 5 products · Limited Use, codes 646 (1), General benefit (4) · strengths: 100U/mL · Inj Sol-10mL Pk, Inj Sol-10mL Vial Pk, Inj Sol-5x3mL Cart Pk, Inj Sol-5X3mL Pref Pen Pk, Inj Sol-5x3mL SoloSTAR Pref Pen Pk

INSULIN GLULISINE (DNA ORIGIN)

· 3 products · General benefit · strengths: 100U/mL · Inj 5x3mL Cart ClickStar Pen, Inj Sol-10mL Vial, Inj Sol-5x3mL SoloSTAR Pref Pen

INSULIN HUMAN BIOSYNTHETIC

· 2 products · General benefit · strengths: 1000U/10mL, 100U/mL · Inj Sol-10mL Pk, Inj Sol-5x3mL Pk

INSULIN INJECTION, HUMAN BIOSYNTHETIC

· 1 products · General benefit · strengths: 500U/mL · Inj Sol-Pref Pen 2x3mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:10
Full class listing Related classes: 68:20:02 Oral Anti-Diabetic Agents, 68:20:06 Incretin Mimetics, 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: diabetes, diabetes requiring daily doses of more than 20 units of fast-acting insulin, the initial stabilization of diabetes
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: INSULIN LISPRO & INSULIN LISPRO PROTAMINE, INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70%, INSULIN HUMAN BIOSYNTHETIC INSULIN LISPRO & INSULIN LISPRO PROTAMINE · General benefit INDICATIONS AND CLINICAL USE HUMALOG (insulin lispro injection), HUMALOG MIX25 (25% insulin lispro injection, 75% insulin lispro protamine suspension), and HUMALOG MIX50 (50% insulin lispro injection, 50% insulin lispro protamine suspension) are indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. PM: https://pdf.hres.ca/dpd_pm/00063278.PDF; date April 12, 2021; DIN 02240294; fetched 2026-09-10 Product monograph HUMALOG insulins are also indicated for the initial stabilization of diabetes mellitus. PM: https://pdf.hres.ca/dpd_pm/00063278.PDF; date April 12, 2021; DIN 02240294; fetched 2026-09-10 Product monograph HUMALOG 200 units/mL KwikPen (insulin lispro injection) is reserved for the treatment of patients with diabetes requiring daily doses of more than 20 units of fast-acting insulin. PM: https://pdf.hres.ca/dpd_pm/00063278.PDF; date April 12, 2021; DIN 02240294; fetched 2026-09-10 Product monograph INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC · General benefit 1 INDICATIONS Novolin®ge (Insulin, Human Biosynthetic) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024217; fetched 2026-09-10 Product monograph INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC · General benefit 1 INDICATIONS Novolin®ge (Insulin, Human Biosynthetic) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024225; fetched 2026-09-10 Product monograph INSULIN ASPART · Limited Use, codes 646 (1), General benefit (4) 1 Indications NOVORAPID® (insulin aspart) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00084670.PDF; date 2026-05-12; DIN 02245397; fetched 2026-09-10 Product monograph • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. NOVORAPID® should normally be used in regimens together with an intermediate or long-acting insulin. NOVORAPID® (10 mL vials) may also be used for continuous subcutaneous insulin infusion (CSII) in pump systems which are licensed in Canada for insulin infusion. PM: https://pdf.hres.ca/dpd_pm/00084670.PDF; date 2026-05-12; DIN 02245397; fetched 2026-09-10 Product monograph INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70% · General benefit  The treatment of adult patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00062479.PDF; date JUL 11, 2017; DIN 02265435; fetched 2026-09-10 Product monograph INSULIN HUMAN BIOSYNTHETIC · General benefit 1 INDICATIONS Novolin®ge (Insulin, Human Biosynthetic) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024233; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE HUMALOG (insulin lispro injection), HUMALOG MIX25 (25% insulin lispro injection, 75% insulin lispro protamine suspension), and HUMALOG MIX50 (50% insulin lispro injection, 50% insulin lispro protamine suspension) are indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. HUMALOG insulins are also indicated for the initial stabilization of diabetes mellitus. HUMALOG (insulin lispro injection) is a fast-acting insulin analogue and is for use in conjunction with a longer HUMALOG, HUMALOG 200 units/mL KwikPen, HUMALOG MIX25, HUMALOG MIX50 Page 3 of 63 acting insulin, such as HUMULIN N (insulin isophane (rDNA origin) NPH), except when used in a subcutaneous insulin infusion pump. HUMALOG 200 units/mL KwikPen (insulin lispro injection) is reserved for the treatment of patients with diabetes requiring daily doses of more than 20 units of fast-acting insulin. https://pdf.hres.ca/dpd_pm/00063278.PDF PM date: April 12, 2021 Source product: HUMALOG; DIN 02229704; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Humalog · DIN 02229704 Shortage status: discontinued (2024-12-10, reported by ELI LILLY CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02229704

Check this DIN again